RxDoctor Payments DataLook up a doctor →

Duane Birky, MD

Neurology · Little Rock, ARNPI 1710974647

Payments from drug & device makers

$11,799in general payments, 2019–2025

Across 637 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$1K
  • Amgen$1K
  • Pfizer$783
  • Lilly USA, LLC$568
  • AbbVie$537
  • Mallinckrodt Hospital Products Inc.$525
  • plus $7K from 46 others

What the payments were for

  • Consulting fees$3003%
  • Food & beverage$11,11894%
  • Education$3813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,799 in reported general payments places this provider in the 65th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$84,905
Medicare patients
603
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sodium Oxybate11$202,759
Nurtec OdtRimegepant Sulfate92$111,179
Emgality PenGalcanezumab-Gnlm122$91,422
UbrelvyUbrogepant44$62,821
BriviactBrivaracetam30$43,708
Aimovig AutoinjectorErenumab-Aooe41$38,754
XcopriCenobamate16$17,729
Ajovy AutoinjectorFremanezumab-Vfrm18$12,944
Lacosamide81$9,809
ReyvowLasmiditan Succinate12$9,312
BelsomraSuvorexant19$8,949
Ajovy SyringeFremanezumab-Vfrm11$7,562
Pregabalin169$6,121
Protriptyline Hcl27$3,751
Armodafinil59$2,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$783$111,17992 claims
AbbVieUbrelvy$537$62,82144 claims
UCB, Inc.Briviact$420$43,70830 claims
SK Life Science, Inc.Xcopri$480$17,72916 claims
Lilly USA, LLCReyvow$568$9,31212 claims
MerckBelsomra$17$8,94919 claims
Upsher-smith Laboratories LLCTopiramate$268$885107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 93 neurology providers in Arkansas.

Other neurology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →